Loading organizations...
Arbor Biotechnologies is a Cambridge, Massachusetts-based biotechnology company that discovers and develops next-generation genetic medicines and novel gene-editing tools using artificial intelligence and machine learning. The organization integrates computational search, genome sequencing, gene synthesis, and high-throughput screening to identify novel CRISPR nucleases from massive protein databases for the treatment of liver and central nervous system diseases. Operating with a workforce of approximately 40 employees, the enterprise has secured over $300 million in total venture funding to date, which includes an oversubscribed $215 million Series B financing round. Arbor Biotechnologies is backed by prominent institutional investors such as ARCH Venture Partners, Temasek, and Andreessen Horowitz, and maintains a strategic research collaboration and licensing agreement with Vertex Pharmaceuticals. The biotechnology enterprise was officially founded in 2016 by CRISPR pioneer Feng Zhang, alongside David Walt, David Scott, and Winston Yan.
Arbor Biotechnologies has raised $289.0M across 2 funding rounds.
Arbor Biotechnologies has raised $289.0M in total across 2 funding rounds.
Arbor Biotechnologies is a clinical‑stage, next‑generation gene‑editing company that discovers and develops programmable DNA editors to create potentially curative genomic medicines, with an initial clinical focus on liver and CNS diseases and a toolbox spanning knockouts, excisions, large insertions and reverse‑transcriptase‑based edits[4][1].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Quick fact box (concise):
If you want, I can: provide a timeline of Arbor’s key publications and partnerships, a deeper technical comparison of their editors versus other next‑generation editors, or a one‑page investor‑style summary of risks and milestones to watch.
Arbor Biotechnologies has raised $289.0M in total across 2 funding rounds.
Arbor Biotechnologies's investors include ARCH Venture Partners, Forbion, Nextech Invest, Frank Yu, Chen Yu, Temasek, ArrowMark Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital.
Arbor Biotechnologies has raised $289.0M across 2 funding rounds. Most recently, it raised $74.0M Series C in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2025 | $74M Series C | — | ARCH Venture Partners, Forbion, Nextech Invest | Announced |
| Nov 9, 2021 | $215M Series B | Frank YU, Chen YU, Temasek | ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, ONO Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, TAO Capital Partners, Tekla Capital Management, T. Rowe Price Associates, Vertex, Woodline Partners | Announced |